2. Summarized data of ongoing trials.
| Clinical trial name | Clinicaltrial.gov ID | Phase | Settings | Drug treatment | Primary endpoints |
| 1L, first-line; 2L, second-line; 3L, third-line; ORR, overall response rate; DOR, duration of response; PFS, progression-free survival; OS, overall survival; BOR, best overall response; EFS, event-free survival; pCR, pathological complete response. | |||||
| MORPHEUS | NCT03193190, NCT03281369, NCT03555149 | I/II | 1L or 2L | Atezolizumab + bevacizumab, BL-8040, cobimetinib, imprime PGG, linagliptin, PEGPH20, RO6874281, selicrelumab | ORR |
| FRACTION-GC | NCT02935634 | II | All | Nivolumab + ipilimumab
Nivolumab + relatlimab Nivolumab + BMS-986205 |
ORR, DOR, PFS rate |
| INTEGA | NCT03409848 | III | 1L | Nivolumab + ipilimumab + trastuzumab
Nivolumab + mFOLFOX6 + trastuzumab |
PFS, OS |
| CA224-060 | NCT03662659 | II | 1L | Relatlimab + nivolumab + chemotherapy
Nivolumab + chemotherapy |
ORR |
| N/A | NCT02901301 | I/II | 1L | Pembrolizumab + trastuzumab + capecitabine + cisplatin | ORR |
| N/A | NCT02013154 | I | 2L+ | DKN-01 + pembrolizumab | Recommended dose |
| N/A | NCT01633970 | I | 2L+ | Atezolizumab + bevacizumab ± chemotherapy | Recommended dose |
| N/A | NCT01968109 | I/II | All | Relatlimab + nivolumab | ORR, DOR, PFS rate |
| N/A | NCT03126110 | I/II | 2L+ | INCAGN01876 + nivolumab + ipilimumab | ORR |
| N/A | NCT02954536 | II | 1L | Pembrolizumab + trastuzumab + capecitabine + cisplatin | PFS |
| N/A | NCT02830594 | I | All | Pembrolizumab + radiotherapy | T cell counts |
| N/A | NCT03122548 | II | 2L+ | Pembrolizumab + CRS-207 | ORR |
| N/A | NCT03342417 | I/II | 2L+ | Nivolumab + ipilimumab | ORR, BOR |
| N/A | UMIN000025947 | I/II | 2L | Paclitaxel + ramucirumab + nivolumab | 6-month PFS rate |
| KEYNOTE-585 | NCT03221426 | III | 1L | Pembrolizumab + cisplatin + capecitabine + 5-fluorouracil
Pembrolizumab + 5-fluorouracil + docetaxel + oxaliplatin + leucovorin |
OS, EFS, pCR rate |
| KEYNOTE-659 | NCT03382600 | II | 1L | Pembrolizumab + TS-1 + cisplatin/oxaliplatin | ORR |
| CheckMate-649 | NCT02872116 | III | 1L | Nivolumab + ipilimumab
Nivolumab + oxaliplatin + capecitabine Nivolumab + oxaliplatin + leucovorin + fluorouracil |
OS, PFS |
| ATTRACTION-4 | NCT02746796 | II/III | 1L | Nivolumab + oxaliplatin + S-1 + capecitabine | OS, PFS |
| KEYNOTE-811 | NCT03615326 | III | 1L | Pembrolizumab + trastuzumab + chemotherapy | PFS, OS |